Evolving management of patients treated by drug-eluting stent: Prevention of late events
Summary: Drug eluting stents (DES) were introduced in clinical practice to overcome the problem of in-stent restenosis (ISR) that limited the overall efficacy of percutaneous coronary revascularization with bare metal stent (BMS). Long-term outcome data confirm a sustained benefit of DES as compared...
Main Authors: | Niccoli, G, Sgueglia, G, Montone, R, Roberto, M, Banning, A, Crea, F |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2014
|
Similar Items
-
Evolving management of patients treated by drug-eluting stent: prevention of late events.
by: Niccoli, G, et al.
Published: (2014) -
Use of a sirolimus-eluting stent to treat failure of a nonpolymer release paclitaxel-eluting stent implanted for in-stent restenosis.
by: Porto, I, et al.
Published: (2005) -
Late stent thrombosis 28 months post implantation of a left main coronary drug-eluting stent.
by: Schrale, R, et al.
Published: (2007) -
Which patients receiving warfarin can be treated safely with a drug-eluting stent?
by: Ryding, A, et al.
Published: (2008) -
Treatment of spontaneous coronary dissection with drug-eluting stents--late clinical, angiographic and IVUS follow up.
by: van Gaal, W, et al.
Published: (2006)